Brief: Organogenesis Provides Update On Second Phase 3 Renu Study
25/09/2025 22:27
Sept 25 (Reuters) - Organogenesis Holdings Inc ORGO.O: ORGANOGENESIS PROVIDES UPDATE ON SECOND PHASE 3 RENU® STUDY ORGANOGENESIS HOLDINGS INC - PHASE 3 TRIAL OF RENU DID NOT MEET PRIMARY ENDPOINT ORGANOGENESIS HOLDINGS INC - TO REQUEST PRE-BLA MEETING WITH FDA FOR RENU ORGANOGENESIS HOLDINGS INC - RENU SHOWS BASELINE PAIN REDUCTION OF -6.9 IN SECOND PHASE 3 STUDY ORGANOGENESIS HOLDINGS INC - RENU SHOWS STATISTICALLY SIGNIFICANT MAINTENANCE OF FUNCTION Source text: ID:nGNX7NdysP Further company coverage: ORGO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Organogenesis Holdings
See all newsBrief: Organogenesis Announces Publication Of Peer-Reviewed Prepare Trial Results
Organogenesis Holdings Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Organogenesis Q2 Net Product Revenue USD 42.8 Million
Organogenesis Holdings Inc. expected to post a loss of 35 cents a share - Earnings Preview
Brief: Organogenesis Announces Publication Of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit Of Affinity™ In The Most Challenging And Complex Venous Leg Ulcers